



NNECOS News

an email publication of Northern New England Clinical Oncology Society

Autumn 2006

Volume 2 Issue 3

NNECOS 2006 ANNUAL MEETING COMES TO PORTLAND, MAINE

Book Your Room by Wednesday October 4th!

Early Registration Deadline is Thursday October 5th

It's time to register for NNECOS' 2006 Annual Meeting being held at the Portland Regency Friday November 3rd and Saturday November 4th. Registration materials are available on our website at www.nnecos.org (click on Events). Please note two important deadlines:

- NNECOS' sleeping room block closes TOMORROW, October 4th.
- Early bird registration deadline is Thursday October 5th. Be sure that your registration is postmarked by Thursday to secure discounted registration rates.

TREMENDOUS RESPONSE TO NNECOS' INAUGURAL ABSTRACT PROGRAM!

Twenty-three Abstracts Selected for Presentation

NNECOS' Annual Meetings just keep getting better. Thanks to our academic enhancement initiative and the generous support of ASCO's \$5,000 grant, we're pleased to announce that twenty-three abstracts from across the region have been chosen to be shared at our 2006 Annual Meeting. You won't want to miss our poster session presentation Friday evening beginning at 5:15pm. Special congratulations to the four abstracts selected to be highlighted during podium presentation Saturday November 4th at 1:00pm:

- Ronald Barkley, MS, JD, NH Oncology Hematology
Effective Patient Advocacy in the Community Practice Setting
- Melissa Bennett, RN, Dartmouth-Hitchcock Medical Center
Strategies to decrease the morbidity associated with central venous catheters in the bone marrow transplant patient population; a quality improvement project.
- Michael A. Jones, MD, Maine Medical Center
Utility and Cost Benefit of Frozen Section Analysis (FS) in the Surgical Management of Thyroid Nodules Based on Pre-Operative Fine Needle Aspiration (FNA) Diagnosis
- Arthur J. Weiss, MD, Little Deer Isle, ME
Detection and characterization of carcinoma cells in the blood.

We look forward to having you as a participant for this exceptional educational weekend in the historic Old Port of Portland, Maine.



PREGNANT WITH CANCER NETWORK, A NETWORK OF HOPE

The Pregnant with Cancer Network is a national organization created to offer hope and support to women who are diagnosed with cancer while pregnant. The mission of the Pregnant with Cancer Network (PWCN) is to let women know they are not alone facing cancer while pregnant.

PWCN was formed in 1997 by three women from Western New York who all faced cancer while pregnant. These women were put in touch with each other during the time surrounding their similar diagnoses. The three women felt fortunate to have each other to share their journey with, but knew that not all women in their circumstances had such support. It was from this concern that Pregnant with Cancer Network was formed.

PWCN maintains a database of women who have survived cancer while pregnant. When a woman contacts us who is pregnant with cancer, we search our network to find a woman whose diagnosis was similar. This support woman then contacts the pregnant mother to lend support, share her experience, and offer hope. We have recently developed a DVD prepared by licensed professionals to train the volunteer support women in our network.

Pregnant with Cancer Network is a 501(c)(3) not-for-profit charitable organization. For more information visit www.pregnantwithcancer.org, telephone 1-800-743-4471, or email info@pregnantwithcancer.org.

YOUR FEEDBACK IS IMPORTANT TO US

We are interested in your feedback and suggestions. Please send your comments and suggestions for future issues to necos@comcast.net.

Feel free to forward this issue of NNECOS News to your colleagues who may not be current members of Northern New England Clinical Oncology Society. *If you would prefer not to receive future email correspondence from NNECOS, please reply to this message and type "remove" in the subject line.*

NEWS FROM OUR SPONSORS

"News from our Sponsors" will be included in NNECOS News on a space available basis, with preference being given to sponsors who have not shared news in the previous two issues. Send your submissions to nnecos@comcast.net.

LILLY ONCOLOGY

New indication for GEMZAR (Gemcitabine HC1 for Injection)

Ovarian Cancer: GEMZAR in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum based therapy.

Diagnosis Code:

Ovarian Cancer: ICD-9-CM Diagnosis Code 183.0

Myelosuppression is usually the dose-limiting toxicity with GEMZAR therapy.

See complete Warnings, Precautions, Adverse Reactions, and Dosage and Administration sections in the full Prescribing Information.